Security
Monopar Therapeutics Inc. Common Stock · MNPR
MNPRNASDAQCommon stockCurrentCIK 1645469Updated Oct 3, 2026
MNPR price & chart
Loading TradingView…
NASDAQ:MNPR on TradingView ↗In the news
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 140,717,709Source | 60,291,071Source | 7,345,159Source | 13,226,954Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 61,833,552Source | 45,816,289Source | 7,266,080Source | 8,186,194Source |
| Assets, CurrentUSD | 140,462,788Source | 60,291,071Source | 7,332,513Source | 13,165,726Source |
| Operating Lease, Right-of-Use AssetUSD | 254,921Source | 0Source | 12,646Source | 61,228Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,890,156Source | 5,254,300Source | 1,757,393Source | 3,137,302Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 6,692Source | 6,103Source | 14,905Source | 12,947Source |
| Additional Paid in CapitalUSD | — | — | — | 61,871,784Source |
| Retained Earnings (Accumulated Deficit)USD | -89,509,530Source | -75,792,636Source | -60,206,217Source | -51,804,021Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 131,389Source | 35,992Source | -14,132Source | 8,942Source |
| Stockholders' Equity Attributable to ParentUSD | 137,827,553Source | 55,036,771Source | 5,587,766Source | 10,089,652Source |
| Additional Paid in Capital, Common StockUSD | 227,199,002Source | 130,787,312Source | 65,793,210Source | — |
| Liabilities and EquityUSD | 140,717,709Source | 60,291,071Source | 7,345,159Source | 13,226,954Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,735,236Source | — | 1,757,393Source | 3,128,894Source |
| Operating Lease, Liability, CurrentUSD | 90,569Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | 154,920Source | — | 0Source | 8,408Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 12,182,496Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -10,515,638Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,837,877Source | 1,140,785Source | 1,897,849Source | — |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -12,201,291Source | -6,404,139Source | -7,858,293Source | -7,228,559Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -63,453,114Source | -14,338,403Source | 4,927,748Source | -4,918,511Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,132,341Source | 104,220Source | 46,969Source | — |
| Payments for Repurchase of Common StockUSD | 34,999,957Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 91,574,402Source | 59,292,257Source | 2,027,227Source | 32,873Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 16,017,263Source | 38,550,209Source | -920,114Source | -12,117,675Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | 8,186,194Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 1,641,263Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 12,182,496Source |
| General and Administrative ExpenseUSD | 6,800,190Source | 3,155,735Source | 3,231,042Source | 2,945,276Source |
| Income Tax Expense (Benefit)USD | 800Source | 800Source | 800Source | 0Source |
| Investment Income, InterestUSD | 2,987,521Source | 404,020Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -13,716,894Source | -15,586,419Source | -8,402,196Source | -10,515,638Source |
| Operating ExpensesUSD | 16,704,415Source | 16,161,721Source | 8,831,235Source | 10,536,877Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 4,202,245Source | 2,074,196Source | — |
| Proceeds from Stock Options ExercisedUSD | 565,171Source | 84Source | 0Source | 169Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | 15,039Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 0Source | 0Source | — |
| Operating Income (Loss)USD | -16,704,415Source | -16,161,721Source | -8,831,235Source | -10,536,877Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -13,716,095Source | -15,585,619Source | — | — |
| Income Tax Expense (Benefit)USD | 800Source | 800Source | 800Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -13,716,894Source | -15,586,419Source | -8,402,196Source | -10,515,638Source |
| Earnings Per Share, BasicUSD per share | -1.85Source | -4.11Source | -0.61Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 7,411,121Source | 3,790,202Source | 13,823,951Source | 12,718,166Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 800Source | 800Source | 800Source | 0Source |
| General and Administrative ExpenseUSD | 6,800,190Source | 3,155,735Source | 3,231,042Source | 2,945,276Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -13,641,497Source | -15,490,482Source | — | — |
| Interest Income (Expense), NetUSD | — | — | 429,039Source | 21,239Source |
| Investment Income, InterestUSD | 2,987,521Source | 404,020Source | — | — |
| Operating ExpensesUSD | 16,704,415Source | 16,161,721Source | 8,831,235Source | 10,536,877Source |
| Research and Development ExpenseUSD | 9,904,225Source | 13,005,986Source | 5,600,193Source | 7,591,601Source |